Practo vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 52)
Practo logo

Practo

ChallengerHealthcare

Digital Health Platform

India's leading digital health platform — doctor discovery, telemedicine, clinic software, and health plans. FY25 revenue ~₹350-400 Cr; 2026 IPO preparation underway; expanding to UAE and US.

AI VisibilityBeta
Overall Score
C52
Category Rank
#303 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
54
Perplexity
47
Gemini
55

About

Practo is India''s largest digital health platform, providing consumers with doctor discovery, online appointment booking, video consultations, health plans, and diagnostic services. On the B2B side, Practo offers clinic management software used by thousands of healthcare providers across India. Founded in Bengaluru, the company serves a broad population seeking affordable and accessible healthcare, with over 2 lakh (200,000) doctors listed. Practo achieved its first fully profitable quarter in late FY2024 and is on track for sustained profitability, with FY2024–25 revenue estimated at ₹350–400 crore. The company expanded to the UAE in 2025 and launched a U.S. care navigation platform in January 2026, targeting an annualized GMV run-rate of $1B by mid-2026. Practo is preparing for a second-half 2026 IPO in India.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

52
Overall Score
93
#303
Category Rank
#1
79
AI Consensus
80
stable
Trend
stable
54
ChatGPT
94
47
Perplexity
89
55
Gemini
94
54
Claude
92
55
Grok
98

Key Details

Category
Digital Health Platform
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.